AU2014249233A1 - Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof - Google Patents

Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof Download PDF

Info

Publication number
AU2014249233A1
AU2014249233A1 AU2014249233A AU2014249233A AU2014249233A1 AU 2014249233 A1 AU2014249233 A1 AU 2014249233A1 AU 2014249233 A AU2014249233 A AU 2014249233A AU 2014249233 A AU2014249233 A AU 2014249233A AU 2014249233 A1 AU2014249233 A1 AU 2014249233A1
Authority
AU
Australia
Prior art keywords
substituted
alkyl
group
pct
aromatic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014249233A
Other languages
English (en)
Inventor
Dmitry Borkin
Tomasz Cierpicki
Jolanta Grembecka
Jay Hess
Xiaoqin LI
Duxin Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of AU2014249233A1 publication Critical patent/AU2014249233A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014249233A 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof Abandoned AU2014249233A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780099P 2013-03-13 2013-03-13
US61/780,099 2013-03-13
PCT/US2014/022750 WO2014164543A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2014249233A1 true AU2014249233A1 (en) 2015-09-24

Family

ID=51529943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014249233A Abandoned AU2014249233A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Country Status (11)

Country Link
US (4) US9216993B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968342B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016512514A (cg-RX-API-DMAC7.html)
KR (1) KR20150130389A (cg-RX-API-DMAC7.html)
CN (1) CN105188705A (cg-RX-API-DMAC7.html)
AU (1) AU2014249233A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015022602A2 (cg-RX-API-DMAC7.html)
CA (1) CA2904612A1 (cg-RX-API-DMAC7.html)
IL (1) IL241193A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015011576A (cg-RX-API-DMAC7.html)
WO (1) WO2014164543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6535430B2 (ja) * 2012-09-28 2019-06-26 イグニタ、インク. 非定型プロテインキナーゼcのアザキナゾリン阻害薬
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10526341B2 (en) * 2014-11-19 2020-01-07 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (zh) * 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
AU2017212572A1 (en) * 2016-01-26 2018-08-23 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
US10752639B2 (en) 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
ES2831084T3 (es) * 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
TWI753016B (zh) * 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
EA039109B1 (ru) * 2016-12-07 2021-12-06 Кура Онколоджи, Инк. Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения
KR102513564B1 (ko) * 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
CN110691779B (zh) * 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
EP3600313A4 (en) 2017-03-31 2020-09-23 The Regents of The University of Michigan PIPERIDINES AS COVALENT MENINE INHIBITORS
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP7307729B2 (ja) * 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
CN112105621B (zh) * 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US12662494B2 (en) 2018-08-08 2026-06-23 Sumitomo Pharma Co., Ltd. Optically active bridged piperidine derivative
EP3860978A1 (en) 2018-10-03 2021-08-11 The Regents Of The University Of Michigan Small molecule menin inhibitors
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
CA3116141C (en) * 2018-12-06 2023-09-05 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
ES2991429T3 (es) * 2019-02-01 2024-12-03 Univ South Carolina Compuestos de piridina bicíclicos para su uso en el tratamiento del cáncer
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CN112116960B (zh) * 2019-06-20 2024-10-11 中国石油化工股份有限公司 柴油加氢反应的组分含量确定方法、装置
TW202126636A (zh) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 作為menin抑制劑之六氫吡啶化合物
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
AR122159A1 (es) * 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
EP4232020A4 (en) * 2020-10-21 2024-08-07 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
BR112023021040A2 (pt) 2021-05-08 2024-02-06 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AR125866A1 (es) 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
CA3218479A1 (en) 2021-06-01 2022-12-08 Wei Cai Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
WO2022253289A1 (en) 2021-06-03 2022-12-08 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
US20250074910A1 (en) * 2021-12-31 2025-03-06 Hitgen Inc. Menin inhibitor and use thereof
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
AR073739A1 (es) * 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
WO2011014128A1 (en) * 2009-07-30 2011-02-03 National University Of Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
AU2010289321A1 (en) * 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Also Published As

Publication number Publication date
IL241193A0 (en) 2015-11-30
WO2014164543A1 (en) 2014-10-09
US20170253611A1 (en) 2017-09-07
JP2016512514A (ja) 2016-04-28
KR20150130389A (ko) 2015-11-23
US9216993B2 (en) 2015-12-22
US20160137665A1 (en) 2016-05-19
EP2968342A1 (en) 2016-01-20
JP2018115214A (ja) 2018-07-26
US9505782B2 (en) 2016-11-29
BR112015022602A2 (pt) 2017-07-18
EP2968342A4 (en) 2016-07-27
EP2968342B1 (en) 2018-10-03
JP6670885B2 (ja) 2020-03-25
US9505781B2 (en) 2016-11-29
CA2904612A1 (en) 2014-10-09
US10160769B2 (en) 2018-12-25
US20140275070A1 (en) 2014-09-18
US20160046647A1 (en) 2016-02-18
MX2015011576A (es) 2016-05-16
CN105188705A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
EP2968342B1 (en) Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US11866435B2 (en) Heterocyclic compounds as immunomodulators
TWI863945B (zh) 2-側氧基喹唑啉衍生物作為甲硫胺酸腺苷基轉移酶2a抑制劑
ES2615238T3 (es) Derivados de tetrahidroquinolinas como inhibidores de bromodominio
ES2655030T3 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ES2589801T3 (es) Derivados de dihidroquinolina como inhibidores de bromodominio
CN104507933B (zh) 氨基喹唑啉和吡啶并嘧啶衍生物
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
TW201726623A (zh) 作為免疫調節劑之雜環化合物
CN107793413A (zh) 嘧啶杂环化合物及其制备方法和应用
WO2019223766A1 (zh) 一种fgfr抑制剂、其制备方法和在药学上的应用
TW202322796A (zh) 靶向p53突變體的化合物
EA028819B1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
KR20110089418A (ko) 트리아진, 피리미딘 및 피리딘 유사체 및 이의 치료제 및 진단 프로브로의 용도
WO2016058501A1 (zh) 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
WO2022100738A1 (zh) 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用
CA3117512A1 (en) 5-azaindazole derivatives as adenosine receptor antagonists
WO2022017408A1 (zh) 芳胺类衍生物及其制备方法和医药用途
WO2024193703A1 (zh) 三嗪类化合物及其用途
TWI924806B (zh) 具有四氫吲哚-1-甲醯胺作為bcl-2抑制劑之化合物、包含其之組合物與其之用途
JP2024540264A (ja) ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用
CN118974050A (zh) 作为ras信号转导调节剂的稠合杂环化合物
WO2025247401A1 (zh) 一种稠合杂环衍生物及其在医药上的应用
WO2025051148A1 (zh) 含氮杂芳基化合物及其制备方法和应用
CN115515958A (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application